Press archive

HEALIOS IS THE RECIPIENT OF SME PHASE 1 GRANT, AWARDED BY EUROPEAN UNION HORIZON 2020 PROGRAM

April 2019

Basel, Switzerland, April 2019 – Healios is proud to announce that it is the recipient of SME phase 1 grant from the European Union program “Horizon 2020” for its innovation with dreaMS Connect, a solution for patients with multiple sclerosis and their treatment team. SME phase 1 funding will support the preparation of the large SME phase 2 grant application (up to 2.5Mio Euro) for the development and deployment of the dreaMS solution in Europe and the USA. This is the 5th grant supporting the dreaMS innovation.

HEALIOS, TOGETHER WITH UNIVERSITY OF CORDOBA AND IMIBIC ARE THE PROUD RECIPIENTS OF THE DIATOMIC GRANT FOR THEIR PROJECT dreaMS

March 2019

Basel, Switzerland and Córdoba, Spain, March 2019 – Healios, together with the University of Córdoba and Imibic are the proud recipients of the Diatomic grant (2nd call) . The grant was awarded in support of the experimental dreaMS technology in Spain with patients diagnosed with multiple sclerosis and their treatment teams. The goal was to demonstrate the feasibility and clinical value of remote patient monitoring using consumer devices (mobile phones, wearable devices).

HEALIOS AND UNIVERSITY HOSPITALOF BASEL ARE THE PROUD RECIPIENTS OF THE INNOSUISSE GRANT FOR THEIR PROJECT dreaMS, AWARDED BY THE SWISS INNOVATION AGENCY

DEC. 7, 2018

Basel Switzerland, Dec 7, 2018 – Healios, in collaboration with the University Hospital of Basel, Neurology department, a world-leading research center in multiple sclerosis, are proud to announce that they have jointly received one of the largest grants provided by the Swiss Innovation Agency (known as “Innosuisse”), for the development and validation of digital biomarkers in multiple sclerosis using the dreaMS Connect platform.

HEALIOS – PROUD RECIPIENT OF THE “SEAL OF EXCELLENCE” AWARDED BY THE EUROPEAN COMMISION

NOV. 12, 2018

Basel, Switzerland Nov. 12. 2018 – Myhealios is proud to announce that it has received the EU “Seal of Excellence” for dreaMS Connect; its solution for patients with multiple sclerosis and their treatment team. DreaMS aim for approval as a software-based medical device in the EU and US. The Seal of Excellence is considered a high-quality label awarded by the @European commission to projects seen as major innovation with great disruptive impact.

HEALIOS IS THE PROUD RECIPIENT OF THE EUROPEAN INNOLAB GRANT FOR THE DEVELOPMENT OF ITS DREAMS APP, A SOLUTION FOR PATIENT WITH MULTIPLE SCLEROSIS

NOV. 5, 2018

Basel, Switzerland Nov. 5. 2018 – Healios, in collaboration with Innolabs, has received European Innolabs funding for the development of its digital health solution for the treatment of Multiple Sclerosis.

HEALIOS AND GENENTECH START RESILIENCE COACHING RESEARCH PILOT IN MULTIPLE SCLEROSIS

MAY 11, 2018

Flemington, NJ, USA, May 11, 2018 – Healios, in collaboration with Genentech, is starting a research pilot to measure the impact of resilience coaching on Multiple Sclerosis caregivers and their loved ones affected by the illness.

HEALIOS LAUNCHES CIRCADY, THE FIRST INTEGRATED INSOMNIA ASSESSMENT AND TREATMENT PLATFORM

APRIL 30, 2018

Basel, Switzerland, April 30, 2018 – Healios, in collaboration with Cohen Veterans Bioscience and Early Signal, launches Circady, a solution to facilitate the assessment and the treatment of chronic insomnia. The solution will launch in NJ, PA and NY states as part of an initial offering exclusively in the USA.

HEALIOS AND HOSPITAL REINA SOFIA IN MULTIPLE SCLEROSIS COLLABORATION

JAN 20, 2018

Cordoba, Spain, January 20, 2018 – Healios, in collaboration with Hospital Reina Sofía in Córdoba is starting a collaboration to develop a remote monitoring platform for patients diagnosed with Multiple Sclerosis to be used by Neurologists. The aim of the solution is to improve overall clinical intervention, patient outcomes and reduce cost of disease management.

HEALIOS CREATES HEALIOS TECHNOLOGIES SL, IN PARTNERSHIP WITH ADHERA SPAIN SL

NOVEMBER 18, 2017

Basel, Switzerland, November 18, 2017 – Healios creates Healios Technologies SL, in partnership with Adhera Spain SL, to develop new connected care technologies. Healios Technologies is located in Cordoba, Spain, next to one of the leading European computer science universities. Investment will look to develop knowhow in applying data sciences to clinical intervention, including algorithm, machine learning and artificial intelligence.

HEALIOS STARTS A RESEARCH COLLABORATION WITH GENENTECH & ROCHE TO EVALUATE RESILIENCE COACHING IN MULTIPLE SCLEROSIS

MAY 15, 2017

Flemington, NJ, USA, May 15, 2017 – Healios starts a collaboration with Genentech & Roche (its parent company), to develop and research resilience coaching for Multiple Sclerosis caregivers and the patients they care for. The research project will look to establish the disease burden on patients and caregivers and if resilience coaching can be used to reduce such burden and improve both patient and caregiver quality of life. This collaboration is projected to last for 2 years.

HEALIOS ENTERS A CONSORTIUM AGREEMENT WITH THE RESEARCH FOUNDATIONS COHEN VETERANS BIOSCIENCE AND THEIR PARTNERS, EARLY SIGNAL

NOVEMBER 20, 2016

Basel, Switzerland, November 20, 2016 – Healios enters a consortium agreement with the research foundation Cohen Veterans Bioscience and their partners, Early Signal, to evaluate the feasibility of technology-based solution for the diagnosis and treatment of chronic insomnia leveraging mobile and wearable technologies combined with the use of smart algorithms.

HEALIOS STARTS A RESEARCH COLLABORATION WITH ROCHE TO EVALUATE RESILIENCE COACHING FOR ALZHEIMER’S CAREGIVERS

MAY 20, 2016

Basel, Switzerland, May 20, 2016 – Healios starts a collaboration with Roche to develop and research resilience coaching for caregivers of patients diagnosed with Alzheimer’s. The aim is to assess if such intervention can reduce caregiving burden and improve quality of life and as such reduce the ancillary costs associated with Alzheimer’s caregiving.

HEALIOS STARTS A RESEARCH COLLABORATION WITH THE DEPARTMENT OF BEHAVIORAL HEALTH AT RUTGERS UNIVERSITY

OCTOBER 15, 2015

Flemington, NJ, USA, October 15, 2015 – Healios starts a collaboration with the department of behavioral health of Rutgers University, to research the impact of remotely provided manualized psychoeducation on schizophrenia caregivers. This research is funded by a grant from the Van Amerigen foundation, NY. The research results are expected to be released in 2018.

HEALIOS, IN COLLABORATION WITH JANSSEN PHARMACEUTICALS, KICK-OFF FIRST, A MAJOR SCHIZOPHRENIA RANDOMIZED CLINICAL TRIAL

JUNE 15, 2015

Flemington, NJ, USA, June 15, 2015 – Healios, in collaboration with Janssen Pharmaceuticals, starts FIRST, a randomized clinical trial aimed at measuring the impact of psychoeducation on caregivers of patients diagnosed with schizophrenia and the potential impact on patient long-term outcomes. The trial results are expected to be released in 2019.

HEALIOS, IN COLLABORATION WITH JANSSEN PHARMACEUTICALS, ANNOUNCES ITS PLANS TO PILOT IN THE USA THE USE OF REMOTELY PROVIDED PSYCHOEDUCATION

MARCH 15, 2014

Flemington, NJ, USA, March 15, 2014 – Healios, in collaboration with Janssen Pharmaceuticals, announces its plan to pilot in the US the use of remotely provided psychoeducation for schizophrenia caregivers in routine clinical practice. The results of this pilot will help determine the feasibility of a larger scale research collaboration can be conducted in the USA.